Cargando…
Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
Autores principales: | Garrett, Joan T., Chakrabarty, Anindita, Arteaga, Carlos L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122353/ https://www.ncbi.nlm.nih.gov/pubmed/30190795 http://dx.doi.org/10.18632/oncotarget.26017 |
Ejemplares similares
-
Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
por: Garrett, Joan T., et al.
Publicado: (2011) -
Erratum to HTR7 promotes laryngeal cancer growth through PI3K/AKT pathway activation
Publicado: (2022) -
Downregulation of BANCR Promotes Aggressiveness in Papillary Thyroid Cancer via the MAPK and PI3K Pathways: Erratum
por: Zhang, Jinjun, et al.
Publicado: (2023) -
Erratum to “Tollip promotes hepatocellular carcinoma progression via PI3K/AKT pathway”
por: Huang, Lu, et al.
Publicado: (2022) -
Cx43 deficiency confers EMT-mediated tamoxifen resistance to breast cancer via c-Src/PI3K/Akt pathway: Erratum
por: Wu, Deng-Pan, et al.
Publicado: (2022)